PTC Therapeutics Inc (NASDAQ: PTCT) is 9.70% higher on its value in year-to-date trading and has touched a low of $28.72 and a high of $58.38 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The PTCT stock was last observed hovering at around $49.84 in the last trading session, with the day’s loss setting it -0.32%.
Currently trading at $49.52, the stock is 6.67% and -1.82% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.14 million and changing -0.64% at the moment leaves the stock 15.42% off its SMA200. PTCT registered 54.08% gain for a year compared to 6-month gain of 22.33%. The firm has a 50-day simple moving average (SMA 50) of $50.4358 and a 200-day simple moving average (SMA200) of $42.9051.
The stock witnessed a 6.27% loss in the last 1 month and extending the period to 3 months gives it a 7.30%, and is -0.06% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.28% over the week and 6.90% over the month.
PTC Therapeutics Inc (PTCT) has around 939 employees, a market worth around $3.91B and $806.78M in sales. Profit margin for the company is -45.03%. Distance from 52-week low is 72.42% and -15.18% from its 52-week high.
with sales reaching $368.26M over the same period.The EPS is expected to grow by 19.58% this year, but quarterly earnings will post 9.68% year-over-year. Quarterly sales are estimated to grow 75.26% in year-over-year returns.
343.0 institutions hold shares in PTC Therapeutics Inc (PTCT), with institutional investors hold 102.33% of the company’s shares. The shares outstanding are 77.70M, and float is at 76.82M with Short Float at 7.13%. Institutions hold 99.82% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 8.97 million shares valued at $274.42 million. The investor’s holdings represent 11.696 of the PTCT Shares outstanding. As of 2024-06-30, the second largest holder is WELLINGTON MANAGEMENT GROUP LLP with 8.21 million shares valued at $251.02 million to account for 10.6987 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 7.77 million shares representing 10.1299 and valued at over $237.67 million, while RTW INVESTMENTS, LP holds 9.6359 of the shares totaling 7.39 million with a market value of $226.08 million.
PTC Therapeutics Inc (PTCT) Insider Activity
The most recent transaction is an insider sale by Klein Matthew B., the company’s CHIEF EXECUTIVE OFFICER. SEC filings show that Klein Matthew B. sold 2,804 shares of the company’s common stock on Apr 22 ’25 at a price of $48.74 per share for a total of $0.14 million. Following the sale, the insider now owns 0.27 million shares.
Still, SEC filings show that on Apr 02 ’25, Golden Lee Scott (EVP & CHIEF MEDICAL OFFICER) disposed off 897 shares at an average price of $46.95 for $42114.0. The insider now directly holds 75,997 shares of PTC Therapeutics Inc (PTCT).
